
Preventing Infusion-Related Reactions With Intravenous Amivantamab: SKIPPirr, a Phase 2 Study (NCT05663866)

Administration of dexamethasone 8 mg oral twice daily 2 days, 1 day, and 1 hour before (total of 5 doses) IV amivantamab infusion was associated with an approximately 3-fold reduction in IRRs^a



Clinical cutoff: Second day of first IV treatment cycle.

alRR on the first day of the first IV treatment cycle defined as IRR events with onset within 24 hours of the start of the first day of the first IV treatment and prior

to the start of the second day of the IV treatment. bIncludes standard premedications (antihistamines, antipyretics, and glucocorticoids).

dex, dexamethasone; IRR, infusion-related reaction; IV, intravenous.

1. Park K, et al. Lung Cancer. 2023;178:166-171.

RYBREVANT® IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

RYBREVANT[®] can cause infusion-related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT[®] with LAZCLUZE[™]

RYBREVANT[®] in combination with LAZCLUZE[™] can cause infusion-related reactions. In MARIPOSA (n=421), IRRs occurred in 63% of patients treated with RYBREVANT[®] in combination with LAZCLUZE[™], including Grade 3 in 5% and Grade 4 in 1% of patients. The incidence of infusion modifications due to IRR was 54% of patients, and IRRs leading to dose reduction of RYBREVANT[®] occurred in 0.7% of patients. Infusion-related reactions leading to permanent discontinuation of RYBREVANT[®] occurred in 4.5% of patients receiving RYBREVANT[®] in combination with LAZCLUZE[™].

RYBREVANT[®] with Carboplatin and Pemetrexed

In PAPILLON (n=151), infusion-related reactions occurred in 42% of patients treated with RYBREVANT[®] in combination with carboplatin and pemetrexed, including Grade 3 (1.3%) adverse

reactions. The incidence of infusion modifications due to IRR was 40%, and 0.7% of patients permanently discontinued RYBREVANT[®].

RYBREVANT[®] as a Single Agent

In CHRYSALIS (n=302), IRR occurred in 66% of patients treated with RYBREVANT[®]. Among patients receiving treatment on Week 1 Day 1, 65% experienced an IRR, while the incidence of IRR was 3.4% with the Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRRs, 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62% and 1.3% of patients permanently discontinued RYBREVANT[®] due to IRR.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT[®] as recommended. Administer RYBREVANT[®] via a peripheral line on Week 1 and Week 2 to reduce the risk of infusion-related reactions. Monitor patients for signs and symptoms of infusion reactions during RYBREVANT[®] infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT[®] based on severity.

Interstitial Lung Disease/Pneumonitis

RYBREVANT[®] can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT[®] with LAZCLUZE™

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients treated with RYBREVANT[®] in combination with LAZCLUZE[™], including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case (0.2%) of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT[®] and LAZCLUZE[™] due to ILD/pneumonitis.

RYBREVANT[®] with Carboplatin and Pemetrexed

In PAPILLON, Grade 3 ILD/pneumonitis occurred in 2.6% of patients treated with RYBREVANT[®] in combination with carboplatin and pemetrexed, all patients required permanent discontinuation.

RYBREVANT[®] as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients treated with RYBREVANT[®], with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) discontinued RYBREVANT[®] due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). For patients receiving RYBREVANT[®] in combination with LAZCLUZE[™], immediately withhold both drugs in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed. For patients receiving RYBREVANT[®] as a single agent or in combination with carboplatin and pemetrexed, immediately withhold RYBREVANT[®] in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis and pemetrexed, immediately withhold RYBREVANT[®] is confirmed.

Venous Thromboembolic (VTE) Events with Concomitant Use of RYBREVANT[®] and LAZCLUZE[™]

RYBREVANT[®] in combination with LAZCLUZE[™] can cause serious and fatal venous thromboembolic (VTEs) events, including deep vein thrombosis and pulmonary embolism. The majority of these events occurred during the first four months of therapy.

In MARIPOSA, VTEs occurred in 36% of patients receiving RYBREVANT[®] in combination with LAZCLUZE[™], including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT[®], and 7% of patients had VTE leading to dose interruptions of LAZCLUZE[™]; 1% of patients had VTE leading to dose reductions of RYBREVANT[®], and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE[™]; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of RYBREVANT[®], and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE[™]. The median time to onset of VTEs was 84 days (range: 6 to 777).

Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended. Monitor for signs and symptoms of VTE events and treat as medically appropriate.

Withhold RYBREVANT[®] and LAZCLUZE[™] based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT[®] and LAZCLUZE[™] at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT[®] and continue treatment with LAZCLUZE[™] at the same dose level at the discretion of the healthcare provider.

Dermatologic Adverse Reactions

RYBREVANT[®] can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus, and dry skin.

RYBREVANT[®] with LAZCLUZE™

In MARIPOSA, rash occurred in 86% of patients treated with RYBREVANT[®] in combination with LAZCLUZE[™], including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT[®] and 30% for LAZCLUZE[™], rash leading to dose reductions occurred in 23% of patients for RYBREVANT[®] and 19% for LAZCLUZE[™], and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT[®] and 1.7% for LAZCLUZE[™].

RYBREVANT[®] with Carboplatin and Pemetrexed

In PAPILLON, rash occurred in 89% of patients treated with RYBREVANT[®] in combination with carboplatin and pemetrexed, including Grade 3 (19%) adverse reactions. Rash leading to dose reductions occurred in 19% of patients, and 2% permanently discontinued RYBREVANT[®] and 1.3% discontinued pemetrexed.

RYBREVANT[®] as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients treated with RYBREVANT[®] as a single agent, including Grade 3 rash in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT[®] was permanently discontinued due to rash in 0.7% of patients.

Toxic epidermal necrolysis occurred in one patient (0.3%) treated with RYBREVANT[®] as a single agent.

Instruct patients to limit sun exposure during and for 2 months after treatment with RYBREVANT[®] or LAZCLUZE[™] in combination with RYBREVANT[®]. Advise patients to wear protective clothing and use broad-spectrum UVA/UVB sunscreen. Alcohol-free (e.g., isopropanol-free, ethanol-free) emollient cream is recommended for dry skin.

When initiating RYBREVANT[®] treatment with or without LAZCLUZE[™], administer alcohol-free emollient cream to reduce the risk of dermatologic adverse reactions. Consider prophylactic measures (e.g. use of oral antibiotics) to reduce the risk of dermatologic reactions. If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT[®] in combination with LAZCLUZE[™], withhold, dose reduce or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT[®] as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT[®] based on severity.

Ocular Toxicity

RYBREVANT[®] can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus, and uveitis.

RYBREVANT[®] with LAZCLUZE™

In MARIPOSA, ocular toxicity occurred in 16% of patients treated with RYBREVANT[®] in combination with LAZCLUZE[™], including Grade 3 or 4 ocular toxicity in 0.7% of patients. Withhold, reduce the dose, or permanently discontinue RYBREVANT[®] and continue LAZCLUZE[™] based on severity.

RYBREVANT[®] with Carboplatin and Pemetrexed

In PAPILLON, ocular toxicity including blepharitis, dry eye, conjunctival redness, blurred vision, and eye pruritus occurred in 9%. All events were Grade 1-2.

RYBREVANT[®] as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients treated with RYBREVANT[®]. All events were Grade 1-2.

Promptly refer patients with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT[®] based on severity.

Embryo-Fetal Toxicity

Based on its mechanism of action and findings from animal models, RYBREVANT[®] and LAZCLUZE[™] can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus.

Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT[®].

Advise females of reproductive potential to use effective contraception during treatment with LAZCLUZE[™] and for 3 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LAZCLUZE[™] and for 3 weeks after the last dose.

Adverse Reactions

RYBREVANT[®] with LAZCLUZE™

For the 421 patients in the MARIPOSA clinical trial who received RYBREVANT[®] in combination with LAZCLUZETM, the most common adverse reactions (\geq 20%) were rash (86%), nail toxicity (71%), infusion-related reactions (RYBREVANT[®], 63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), nausea (21%), and ocular toxicity (16%). The most common Grade 3 or 4 laboratory abnormalities (\geq 2%) were decreased albumin

(8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).

Serious adverse reactions occurred in 49% of patients who received RYBREVANT[®] in combination with LAZCLUZE[™]. Serious adverse reactions occurring in ≥2% of patients included VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and infusion-related reaction (RYBREVANT[®]) (2.1% each). Fatal adverse reactions occurred in 7% of patients who received RYBREVANT[®] in combination with LAZCLUZE[™] due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).

RYBREVANT[®] with Carboplatin and Pemetrexed

For the 151 patients in the PAPILLON clinical trial who received RYBREVANT[®] in combination with carboplatin and pemetrexed, the most common adverse reactions (\geq 20%) were rash (90%), nail toxicity (62%), stomatitis (43%), infusion-related reaction (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (\geq 2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).

Serious adverse reactions occurred in 37% of patients who received RYBREVANT[®] in combination with carboplatin and pemetrexed. Serious adverse reactions in $\geq 2\%$ of patients included rash, pneumonia, ILD,

pulmonary embolism, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.

RYBREVANT[®] as a Single Agent

For the 129 patients in the CHRYSALIS clinical trial who received RYBREVANT[®] as a single agent, the most common adverse reactions (\geq 20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (\geq 2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Serious adverse reactions occurred in 30% of patients who received RYBREVANT[®]. Serious adverse reactions in \geq 2% of patients included pulmonary embolism, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.

LAZCLUZE[™] Drug Interactions

Avoid concomitant use of LAZCLUZE[™] with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.

Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.

Please read full **Prescribing Information** for RYBREVANT[®].

Please read full <u>Prescribing Information</u> for LAZCLUZE[™].